Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma With Kami Maddocks, MD, and Kelly Brassil, PhD, RN, FAAN

Hodgkin lymphoma is a rare malignancy involving the lymph nodes and lymphatic system, with 8,830 new cases diagnosed and accounting for 960 deaths each year in the United States (Siegel et al, 2021). In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during middle age, and is followed by another peak in adults older than 55 (NCCN, 2020). There are 2 main types of HL: classical HL, which accounts for 95% of...
Continue reading

Pembrolizumab Approved for Classical Hodgkin Lymphoma

PembrolizumabThe FDA has now expanded the approved indications for pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) to include both adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy. The approval was based on efficacy data from the open-label phase 3 KEYNOTE-204 trial (NCT02684292), for which 304 adult patients with cHL previously treated with at least one multiagen...
Continue reading

Modern Radiation Therapy Doses for Early-Stage Hodgkin Lymphoma: Chelsea Pinnix, MD, PhD

While radiation therapy is an effective treatment for patients with early-stage favorable Hodgkin lymphoma, it also poses a risk of long-term toxicity to the surrounding organs and tissue. In a study recently published in JAMA Network Open, a team of researchers led by first author Chelsea Pinnix, MD, PhD, of MD Anderson Cancer Center, found that combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and contemporary radiation therapy (RT) demonstrated effic...
Continue reading

Modern Radiation Plus Chemo Effective and Safe for Early-Stage Hodgkin Lymphoma

According to the results of a new study, combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) followed by contemporary radiation therapy (RT) was effective and safe in patients with early-stage favorable Hodgkin lymphoma, with low radiation doses delivered to at-risk organs. "While maximal efficacy is demonstrated with combined modality therapy, RT is often omitted in fear of late adverse effects," write the investigators, led by first author Chelsea C. Pi...
Continue reading

Treatment Challenges and Advances in Hodgkin Lymphoma: Craig Moskowitz, MD, and Kami Maddocks, MD

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the management of relapsed/refractory classical Hodgkin lymphoma (HL) and the advances brought to the treatment of this disease by dev...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright ┬ę 2021 Oncology Data Advisor. All rights reserved.